Gender-specific effects in the treatment of acute schizophrenia with risperidone

Pharmacopsychiatry

Volumn 39, Issue 5, 2006, Pages 171-174

  Raedler, Tomas J ^a   Schreiner, A ^b   Naber, D ^a   Wiedemann, K ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Janssen Cilag ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BIPERIDEN; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIAZEPAM; LORAZEPAM; RISPERIDONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; MAXIMUM PERMISSIBLE DOSE; PRIORITY JOURNAL; SCHIZOPHRENIA; SEX DIFFERENCE; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTI-ANXIETY AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT DROPOUTS; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SEX CHARACTERISTICS; SEX FACTORS; TREATMENT OUTCOME;

EID: 33748542619     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-948327     Document Type: Article

References (24)

1. Aichhorn W, Weiss U, Marksteiner J, Kemmler G, Walch T, Zernig G et al. Influence of age and gender on risperidone plasma concentrations. J Psychopharmacol 2005; 19: 395-401
2. Castle DJ, McGrath J, Kulkarni J. Women and schizophrenia. Cambridge, UK: Cambridge University Press, 2000
3. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13: 25-40
4. Csernansky JG, Mahmoud R, Brenner R. The Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346: 16-22
5. Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry 2001; 62: 153-157
6. Davis JM, Chen N, Click ID. A Meta-analysis of the Efficacy of Second-Generation Antipsychotics. Arch Gen Psychiatry 2003; 60: 553-564
7. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health and Welfare. Washington, D.C. 1976; 338: 534-537
8. Hafner H. Gender differences in schizophrenia. Psychoneuroendocrinology 2003; 28 (Suppl 2): 17-54
9. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995; 50: 222-239
10. Hunter RH, Joy CB, Kennedy E, Gilbody SM, Song F. Risperidone versus typical antipsychotic medication for schizophrenia (Cochrane Review). Cochrane Database Syst Rev 2003; 2: CD000440
11. th ed. Philadelphia: Lippincott Williams & Wilkins, 1997
12. Kay SR, Opler LA, Fiszbein A. Positive and negative symptoms in schizophrenia: assessment and research. New York: Bruner Mazel, 1991
13. Labelle A, Light M, Dunbar F. Risperidone treatment of outpatients with schizophrenia: no evidence of sex differences in treatment response. Can J Psychiatry 2001; 46: 534-541
14. Lane HY, Chang YC, Chiu CC, Chen TT, Lee SH, Chang WH. Influences of patient-related variables on risperidone efficacy for acutely exacerbated schizophrenia: analyses with rigorous statistics. J Clin Psychopharmacol 2002; 22: 353-358
15. Lemmens P, Brecher M, Van Baelen B. A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. Acta Psychiatr Scand 1999; 99: 160-170
16. Leung A, Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand Suppl 2000; 401: 3-38
17. Leucht S, Barnes TRE, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003; 160: 1209-1222
18. Love RC, Nelson MW. Pharmacology and clinical experience with risperidone. Expert Opin Pharmacother 2000; 1: 1441-1453
19. Melkersson KI, Hulting AL, Rane AJ. Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. Br J Clin Pharmacol 2001; 51: 317-324
20. Raedler TJ, Schreiner A, Naber D, Wiedemann K. Risperidone in the treatment of acute schizophrenia. J Clin Psychopharmacol 2004; 24: 335-338
21. Salokangas RK. Gender and the use of neuroleptics in schizophrenia. Schizophr Res 2004; 66: 41-49
22. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet 2003; 42: 107-121
23. Seeman MV. Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry 2004; 161: 1324-1333
24. Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther 1999; 24: 339-346